Provided by Tiger Fintech (Singapore) Pte. Ltd.

Ocugen

0.6875
+0.01041.54%
Pre-market: 0.70990.0224+3.26%08:25 EDT
Volume:3.00M
Turnover:2.07M
Market Cap:200.76M
PE:-3.45
High:0.7040
Open:0.6795
Low:0.6766
Close:0.6771
Loading ...

Buy Rating for Ocugen Based on Promising OCU410 Study Progress and Geographic Atrophy Treatment Potential

TIPRANKS
·
15 Feb

Why Ocugen (OCGN) Is Advancing Today

Insider Monkey
·
14 Feb

Ocugen Inc. Stock Rises Thursday, Outperforms Market

Dow Jones
·
14 Feb

Ocugen Inc. Stock Advances 6.5%, Outperforms Market

Dow Jones
·
14 Feb

Analysts Offer Insights on Healthcare Companies: Ocugen (OCGN) and Xilio Therapeutics (XLO)

TIPRANKS
·
13 Feb

Ocugen Is Maintained at Buy by Chardan Capital

Dow Jones
·
13 Feb

Ocugen price target raised to $8 from $7 at H.C. Wainwright

TIPRANKS
·
13 Feb

Ocugen Inc - Phase 1/2 Study Shows Favorable Safety Profile for Ocu410

THOMSON REUTERS
·
12 Feb

Ocugen, Inc. Announces Dosing Completion in the Phase 2 Armada Clinical Trial for Ocu410—a Multifunctional Modifier Gene Therapy for the Treatment of Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration

THOMSON REUTERS
·
12 Feb

Ocugen, Inc. Announces Dosing Completion in the Phase 2 ArMaDa Clinical Trial for OCU410—a Multifunctional Modifier Gene Therapy for the Treatment of Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration

GlobeNewswire
·
12 Feb

Ocugen Inc. Stock Falls Tuesday, Underperforms Market

Dow Jones
·
12 Feb

Ocugen Inc. Stock Falls Monday, Underperforms Market

Dow Jones
·
11 Feb

Ocugen Inc. Stock Falls Thursday, Underperforms Market

Dow Jones
·
07 Feb

Ocugen Inc. Stock Rises Tuesday, Outperforms Market

Dow Jones
·
05 Feb

Ocugen Says EMA Panel Issues Positive Opinion for Potential Eye Disease Treatment

MT Newswires Live
·
04 Feb

Ocugen Announces Positive Opinion of European Medicines Agency’s Committee for Advanced Therapies for Advanced Therapy Medicinal Product Classification for Modifier Gene Therapy Candidate Ocu400 for Retinitis Pigmentosa

THOMSON REUTERS
·
03 Feb

Ocugen Announces Positive Opinion of European Medicines Agency’s Committee for Advanced Therapies for Advanced Therapy Medicinal Product Classification for Modifier Gene Therapy Candidate OCU400 for Retinitis Pigmentosa

GlobeNewswire
·
03 Feb

Ocugen Files Secondary Stock Shelf

MT Newswires Live
·
01 Feb

Ocugen Inc. Stock Rises Thursday, Outperforms Market

Dow Jones
·
31 Jan

Ocugen Inc. Stock Falls Tuesday, Underperforms Market

Dow Jones
·
29 Jan